# Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory

> **NIH NIH UM1** · JOHNS HOPKINS UNIVERSITY · 2024 · $5,447,677

## Abstract

ABSTRACT
The immediate establishment of the latent HIV-1 reservoir in resting memory CD4+ T cells precludes HIV-1 cure,
compelling ART for a lifetime in children. The mission of the PAVE Collaboratory is to use cutting-edge science
to establish a deep and broad understanding of the immunopathogenesis of pediatric HIV-1 reservoirs, across
the age spectrum, and to demonstrate preclinical safety and efficacy of novel therapeutics to eradicate reservoirs
and control rebound that will pave the way for future interventional human studies toward a lifetime of sustained
HIV-1 control off ART. We hypothesize that the unique features of the infant immune system at the time of
reservoir establishment impact the characteristics of long-term virus persistence, susceptibility to immune-
mediated clearance, and reactivation that are distinct from adult infections, warranting in-depth investigation to
inform cure therapeutics suitable for children. We will test this hypothesis and execute the PAVE Scientific
Agenda through accomplishment of the following Specific Aims: 1. Define the establishment and evolution of
the HIV latent reservoir in perinatal infection. 2. Enhance pediatric immunity and broadly neutralizing
antibody (bNAb) delivery to achieve post-treatment control of HIV-1 off ART. 3. Deploy immune-targeted
strategies to eliminate virus reservoirs. 4. Optimize virologic, immunologic, and imaging methods to
assess efficacy of HIV-1/S(H)IV cure interventions. 5. Foster community engagement in pediatric HIV
cure research. The PAVE program is multidisciplinary, multicultural, and iterative with a nimble structure
encompassed by four highly synergistic Research Foci and a domestic and international community program
that will rapidly incorporate new scientific directions and feedback from our stakeholders. The PAVE leadership
team spans diverse scientific expertise and exhibits additional diversity in terms of gender, academic rank, and
country of origin. Each of the Research Foci also includes junior faculty co-Investigators to facilitate their career
development within the HIV-1 research space. Through the collective efforts of our scientific leadership,
Executive Committee, Scientific Advisory Board, investigators, industry partners, network collaborations, and
domestic and international community program, PAVE anticipates meeting the following overall milestones of:
1) understanding early life immunity and early antiretroviral treatment on the composition and stability of the
latent reservoir, including in naïve T cells, and potential for HIV-1 remission; 2) eliminating of these reservoirs in
pre-clinical studies of immune-targeted strategies; 3) defining the role of myeloid cells in HIV-1 persistence and
rebound, including in the CNS; 4) establishing novel approaches to enhance pediatric immunity through active
and passive immunization; 5) developing cutting-edge approaches to quantify and monitor proviral reservoirs to
measure clinical trial efficacy, ...

## Key facts

- **NIH application ID:** 10837009
- **Project number:** 5UM1AI164566-04
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Ann M Chahroudi
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $5,447,677
- **Award type:** 5
- **Project period:** 2021-08-16 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10837009

## Citation

> US National Institutes of Health, RePORTER application 10837009, Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory (5UM1AI164566-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10837009. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*